Recent Quotes
My Watchlist
Indicators
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Axsome Therapeutics, Inc. - Common Stock (NQ:AXSM)

108.86 -2.00 (-1.80%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 608,544
Open 110.18
Bid (Size) 96.00 (1)
Ask (Size) 112.00 (1)
Prev. Close 110.86
Today's Range 108.03 - 112.25
52wk Range 64.11 - 139.13
Shares Outstanding 47,190,970
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Axsome Therapeutics Clocks Around 60% Topline Growth In Q1
Axsome beat Q1 expectations with $121.5 million in revenue and strong Auvelity sales as it prepares Symbravo's U.S. launch and advances key drug programs. 
Via Benzinga
Axsome Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
From Axsome Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
+24.7%
+24.7%
1 Month
+11.6%
+11.6%
3 Month
-0.6%
-0.6%
6 Month
+20.0%
+20.0%
1 Year
+43.8%
+43.8%

More News

Read More
Earnings Scheduled For May 5, 2025
Via Benzinga
Axsome Therapeutics and Mental Health America (MHA) Join Voices to Highlight Mental Health Month
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Deep Dive Into Axsome Therapeutics Stock: Analyst Perspectives (28 Ratings)
Via Benzinga
Axsome Therapeutics to Participate in Upcoming Investor Conferences
From Axsome Therapeutics, Inc.
Via GlobeNewswire
SECURITIES FRAUD CLASS ACTIONS HAVE SURVIVED MOTIONS TO DISMISS: Long-Term Shareholders of Axsome Therapeutics, Inc. (NASDAQ: AXSM); Driven Bands Holdings, Inc. (NASDAQ: DRVN); Mercury Systems, Inc. (NASDAQ: MRCY); and Virtu Financial Inc. (NASDAQ: VIRT)
From Grabar Law Office
Via GlobeNewswire
Attention Long-Term Shareholders of Axsome Therapeutics, Inc. (NASDAQ: AXSM); Driven Bands Holdings, Inc. (NASDAQ: DRVN); Integra Lifesciences Holdings Corporation (NASDAQ: IART); and Virtu Financial Inc. (NASDAQ: VIRT): Grabar Law Office Investigates
From Grabar Law Office
Via GlobeNewswire
ALERT: Grabar Law Office Investigates Claims on Behalf of Shareholders of Axsome Therapeutics, Inc. (NASDAQ: AXSM); BioVie Inc. (NASDAQ: BIVI); Maison Solutions Inc. (NASDAQ: MSS); and Virtu Financial Inc. (NASDAQ: VIRT), as Securities Fraud Class Actions
From Grabar Law Office
Via GlobeNewswire
Axsome Therapeutics to Report First Quarter 2025 Financial Results on May 5
From Axsome Therapeutics, Inc.
Via GlobeNewswire
This Reddit Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Via Benzinga
ALERT: Grabar Law Office Investigates Claims on Behalf of Shareholders of Axsome Therapeutics, Inc. (NASDAQ: AXSM); BioVie Inc. (NASDAQ: BIVI); Maison Solutions Inc. (NASDAQ: MSS); and Virtu Financial Inc. (NASDAQ: VIRT), as Securities Fraud Class Actions
From Grabar Law Office
Via GlobeNewswire
SECURITIES FRAUD CLASS ACTIONS SURVIVE MOTIONS TO DISMISS: Grabar Law Office Investigates Claims on Behalf of Shareholders of Arqit Quantum Inc. (NASDAQ: ARQQ); Axsome Therapeutics, Inc. (NASDAQ: AXSM); BioVie Inc. (NASDAQ: BIVI); and Maison Solutions
From Grabar Law Office
Via GlobeNewswire
Axsome Therapeutics Presents Positive Pivotal Phase 3 Results of the ACCORD-2 Trial of AXS-05 in Alzheimer’s Disease Agitation and the SYMPHONY Trial of AXS-12 in Narcolepsy at the 2025 American Academy of Neurology (AAN) Annual Meeting
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Stocks Edge Higher Despite Trade, Economic Jitters
Via Talk Markets
Topics Stocks / Equities
Why Shares of Axsome Therapeutics Slumped Today
Via The Motley Fool
Axsome Therapeutics Dives Again On Its Second Big Drug Failure In A Week
Via Investor's Business Daily
Axsome's Solriamfetol Fails Primary Goal In Depression Study But Shows Improvements In Associated Sleep Disorder
Via Benzinga
Axsome Therapeutics Announces Topline Results of PARADIGM Phase 3 Proof-of-Concept Trial of Solriamfetol in Major Depressive Disorder (MDD) with and without Excessive Daytime Sleepiness (EDS)
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Celanese To Rally Around 27%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
Breaking Down Axsome Therapeutics: 31 Analysts Share Their Views
Via Benzinga
Why Pharma and Biotech Stocks Got Thrashed on Tuesday
Via The Motley Fool
IBD 50's Axsome Therapeutics Dives On Mixed ADHD Results. Why Analysts Aren't Worried.
Via Investor's Business Daily
Axsome Therapeutics Lower Dose Of Attention Deficient Disorder Candidate Hits Primary Goal
Via Benzinga
Axsome Therapeutics Announces FOCUS Phase 3 Trial of Solriamfetol in Adults with Attention Deficit Hyperactivity Disorder (ADHD) Achieves Primary Endpoint
From Axsome Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Axsome Therapeutics, Inc. - Common Stock publicly traded?
Yes, Axsome Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Axsome Therapeutics, Inc. - Common Stock trade on?
Axsome Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Axsome Therapeutics, Inc. - Common Stock?
The ticker symbol for Axsome Therapeutics, Inc. - Common Stock is AXSM on the Nasdaq Stock Market
What is the current price of Axsome Therapeutics, Inc. - Common Stock?
The current price of Axsome Therapeutics, Inc. - Common Stock is 108.86
When was Axsome Therapeutics, Inc. - Common Stock last traded?
The last trade of Axsome Therapeutics, Inc. - Common Stock was at 05/08/25 04:00 PM ET
What is the market capitalization of Axsome Therapeutics, Inc. - Common Stock?
The market capitalization of Axsome Therapeutics, Inc. - Common Stock is 5.14B
How many shares of Axsome Therapeutics, Inc. - Common Stock are outstanding?
Axsome Therapeutics, Inc. - Common Stock has 5B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.